Sign In
Buy LGND
$234.40
+1.64 (+0.705%)
At Close: Jun 03, 2026
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
02:19pm, Thursday, 08'th May 2025
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis –
Ligand Reports First Quarter 2025 Financial Results
07:00am, Thursday, 08'th May 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Cr
Ligand to Participate in May Investor Conferences
07:00am, Thursday, 01'st May 2025
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
07:00am, Thursday, 24'th Apr 2025
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
06:00am, Thursday, 17'th Apr 2025
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug
Ligand to Participate in March Investor Conferences
07:00am, Monday, 03'rd Mar 2025
JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza w
Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript
03:06pm, Thursday, 27'th Feb 2025
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysi
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
07:00am, Thursday, 27'th Feb 2025
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
07:00am, Tuesday, 25'th Feb 2025
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:00am, Thursday, 06'th Feb 2025
JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Looking Back On Ligand Pharmaceuticals
02:59pm, Monday, 03'rd Feb 2025
Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
06:50am, Sunday, 24'th Nov 2024
I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinf
Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript
08:07am, Friday, 08'th Nov 2024
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
08:01am, Friday, 01'st Nov 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m.
